Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and above.~* Definite diagnosis of acute thrombotic thrombocytopenic purpura (TTP).~* Thrombocytopenia.~* Diagnostic signs of microangiopathic hemolytic anemia.~Exclusion Criteria:~* Congenital thrombotic microangiopathies.~* Alternative secondary cause for microangiopathy.~* Co-morbid illness limiting life expectancy to less than 3 months independent of TTP.~* Patients known to be HIV positive.~* Patients known to have lupus.~* Refusal to accept blood products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Uniplas (Type: EXPERIMENTAL): Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
- Cryosupernatant plasma (Type: ACTIVE_COMPARATOR): Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.

Based on this trial design, predict the completion outcome and termination type (if applicable).